Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation

Latest investor presentation

Latest clinical presentation
Latest quarterly earnings
Annual report

Annual report

Latest publications, posters & presentations

Our research

Global ticker
NASDAQNVAX
Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage
NASDAQNVAX
YearTrailing 12-monthsCalendar year 2023Calendar year 2022Calendar year 2021Calendar year 2020Calendar year 2019Calendar year 2018Calendar year 2017Calendar year 2016Calendar year 2015Calendar year 2014Calendar year 2013Calendar year 2012Calendar year 2011Calendar year 2010Calendar year 2009Calendar year 2008Calendar year 2007Calendar year 2006Calendar year 2005Calendar year 2004Calendar year 2003Calendar year 2002Calendar year 2001Calendar year 2000Calendar year 1999Calendar year 1998Calendar year 1997Calendar year 1996
TypeAll filingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Mar 29, 2005Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
PRER14AProxy soliciting materials. Revised preliminary materialMar 25, 2005Open Proxy soliciting materials. Revised preliminary material in HTML.Open Proxy soliciting materials. Revised preliminary material in DOC file.Open Proxy soliciting materials. Revised preliminary material in PDF file.Open Proxy soliciting materials. Revised preliminary material in XLS file.
DFAN14AAdditional proxy soliciting materials filed by non-managementMar 23, 2005Open Additional proxy soliciting materials filed by non-management in HTML.Open Additional proxy soliciting materials filed by non-management in DOC file.Open Additional proxy soliciting materials filed by non-management in PDF file.Open Additional proxy soliciting materials filed by non-management in XLS file.
PREC14APreliminary proxy statement containing contested solicitationsMar 22, 2005Open Preliminary proxy statement containing contested solicitations in HTML.Open Preliminary proxy statement containing contested solicitations in DOC file.Open Preliminary proxy statement containing contested solicitations in PDF file.Open Preliminary proxy statement containing contested solicitations in XLS file.
PRER14AProxy soliciting materials. Revised preliminary materialMar 18, 2005Open Proxy soliciting materials. Revised preliminary material in HTML.Open Proxy soliciting materials. Revised preliminary material in DOC file.Open Proxy soliciting materials. Revised preliminary material in PDF file.Open Proxy soliciting materials. Revised preliminary material in XLS file.
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMar 10, 2005Open A preliminary proxy statement providing notification matters to be brought to a vote in HTML.Open A preliminary proxy statement providing notification matters to be brought to a vote in DOC file.Open A preliminary proxy statement providing notification matters to be brought to a vote in PDF file.Open A preliminary proxy statement providing notification matters to be brought to a vote in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.